论文部分内容阅读
目的对罗格列酮(文迪雅)单用或与口服降糖药合用治疗伴有代谢综合征2型糖尿病临床疗效及安全性进行观察。方法 68例伴有代谢综合征2型糖尿病患者进行为期12周的文迪雅治疗的观察。结果与基线期相比,文迪雅治疗12周后患者空腹血糖(FBG)、糖化血红蛋白(HbA_1c)、空腹胰岛素(FINS)水平均有显著下降,胰岛素抵抗指数(HOMA 指数)下降,甘油三酯(TG)下降,收缩压和舒张压降低。结论文迪雅是胰岛素增敏剂,有明显的降低2型糖尿病患者 FBG、FINS、HbA_1c,减少胰岛素抵抗的效果,有降压、调脂、保护胰岛功能,是治疗伴有代谢综合征2型糖尿病有效而安全的理想口服降糖药物。
Objective To observe the clinical efficacy and safety of rosiglitazone (Avandia) alone or in combination with oral hypoglycemic agents in the treatment of type 2 diabetes mellitus with metabolic syndrome. Methods 68 patients with metabolic syndrome type 2 diabetes were treated with Avandia for 12 weeks. Results Compared with baseline, the levels of fasting blood glucose (FBG), glycosylated hemoglobin (HbA_1c), fasting insulin (FINS) and the insulin resistance index (HOMA) of Avandia patients decreased after 12 weeks of treatment. The level of triglyceride (TG) decreased systolic and diastolic blood pressure decreased. Conclusion Avandia is an insulin sensitizer with significantly lower FBG, FINS and HbA_1c in type 2 diabetic patients and has the effect of reducing insulin resistance. It has the functions of lowering blood pressure, regulating lipid and protecting the islet function. It is an effective treatment for patients with metabolic syndrome type 2 Diabetes effective and safe ideal oral hypoglycemic agents.